Abiomed gets $16 million towards artificial heart project
This article was originally published in Clinica
Executive Summary
Genzyme General is to buy around 1.2 million shares in Abiomed at $13 a share, which will result in Genzyme owning some 14% of the US developer of cardiac assist systems.